Camurus falls as lower drug sales drive Q1 miss

Camurus AB

12/05/2026 08:25

** Shares in Camurus CAMX.ST fall 8% after the Swedish biopharma group posted weaker-than-expected first quarter results

** Q1 revenue, which consists of drug sales and royalties, came in at 533 million Swedish crowns ($58 million), below the LSEG estimate of 665.2 million

** Q1 drug sales fell 12%, while operating profit of 168 million crowns missed consensus expectations by 29%

** Jefferies says the miss could cut consensus revenue and profit estimates by at least 5% and 8%, respectively, even though the company kept its 2026 financial guidance unchanged

** Kempen says any share price weakness could be an attractive entry point given pipeline catalysts

** Camurus shares are down 18% YTD and sit on bottom of STOXX 600 .STOXX

($1 = 9.2605 Swedish crowns)

 (Reporting by Boleslaw Lasocki)

 ((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))